The good news is that we can increase glutathione levels by supplementation

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema

External resources Sigma-Aldrich - Peptide stability and potential degradation pathways PubMed Central - Factors affecting physical stability of peptide therapeutics For researchers serious about protecting their peptide investments and optimizing every protocol, SeekPeptides provides comprehensive storage guides, stability databases, and handling protocols for members
High levels indicate poor liver function
Long-term users often report that benefits plateau and stabilize rather than continuing to increase indefinitely, which is expected given that glutathione's effects are primarily protective and restorative rather than performance-enhancing beyond normal physiological function
Novo Nordisk has indicated its intention to submit CagriSema for regulatory review following the completion of the REDEFINE Phase 3 programme